New Japanese Regenerative Medicine Legislation and Commercial … – Wall Street Journal
New Japanese Regenerative Medicine Legislation and Commercial …Wall Street Journal25, 2013 (GLOBE NEWSWIRE) — Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today gave an update on new legislation which provides a framework for accelerated approval of stem cell products in Japan, the world’s … and more …read more &nbs… Continue reading
